๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 17 Guangzhou 15 Shanghai 12 Hangzhou 6 Nanjing 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing17 Guangzhou15 Shanghai12 Hangzhou6 Nanjing6
All 37 locations
Target enrolment
to

Trials with a site in Beijing

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
NCT07724535Cancer
Peking University Cancer Hospital & Institute
Phase 1/2
30
Beijing
2026-06-24
Recruiting
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors
NCT07410676Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
Essen Biotech
Phase 1/2
83
Beijing
2026-02-01
Recruiting
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
NCT07410494Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
Essen Biotech
Phase 1/2
85
Beijing
2026-02-01
By invitation
Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors
NCT07656090Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
19
Beijing
2025-12-18
Recruiting
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
NCT07110090Thrombocytopenia, Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
16
Beijing
2025-08-28
Recruiting
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748Cancer
Peking Union Medical College Hospital
Not applicable
120
Beijing
2025-08-01
Not yet open
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy
NCT06716788Cancer
Peking University Cancer Hospital & Institute
Observational
50
Beijing
2025-05-01
Not yet open
EGFR Mutation Targeting Molecular Probe for PET Imaging
NCT06641674Cancer
Peking University Cancer Hospital & Institute
Observational
20
Beijing
2024-11-15
Recruiting
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
NCT06612632Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
100
Beijing
2024-05-24
Recruiting
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
NCT06203119Cancer
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2024-03-06
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Not yet open
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06149533Thrombosis, Venous, Cancer, Catheter Complications
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
Hoffmann-La Roche
Phase 3
100
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
NCT05629234Cancer
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

10 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 17 studies
PhaseStudiesRecruitingShare
Phase 35129.4%
Phase 1/24423.5%
Observational3117.6%
Phase 12211.8%
Not applicable115.9%
Phase 2115.9%
Phase EARLY_PHASE1105.9%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences42
Peking University Cancer Hospital & Institute42
AstraZeneca20
Essen Biotech22
Bayer10
Bristol-Myers Squibb11
Hoffmann-La Roche11
Peking Union Medical College Hospital11
Shanghai Weihe Medical Laboratory Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.